Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 8/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 3/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15676807 | 0.82 | BACE1 (0.48) | GABRA1GABRB2CYP19A1BACE1HTR2A | |
| SCHEMBL1692283 | 0.81 | APP (0.47) | GABRA1GABRB2BACE1HTR2AHTR2C | |
| SCHEMBL1696888 | 0.79 | OXER1 (0.40) | CYP19A1BACE1HTR2AHTR2C | |
| SCHEMBL1691863 | 0.77 | CYP19A1 (0.36) | GABRA1GABRB2CYP19A1BACE1HTR2A | |
| SCHEMBL25081097 | 0.76 | CYP19A1 (0.49) | GABRA1GABRB2CYP19A1HTR2AHTR2C | |
| SCHEMBL31450403 | 0.73 | OXER1 (0.44) | GABRA1GABRB2HTR2ACYP1A2CYP3A4 | |
| SCHEMBL11081014 | 0.73 | ADRA2A (0.50) | CYP19A1HTR2AHTR2CCYP1A2 | |
| SCHEMBL4559781 | 0.72 | OXER1 (0.52) | BACE1 | |
| SCHEMBL14473516 | 0.72 | ADRA2A (0.49) | CYP19A1BACE1HTR2AHTR2CCYP1A2 | |
| SCHEMBL24130695 | 0.72 | CYP19A1 (0.39) | CYP19A1HTR2AHTR2CHTR2BCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166560-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166560-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | F12, F11, F5 | GABRA1 3975/4885GABRB2 4636/4885CYP19A1 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.